Zogenix Completes Enrollment in First ZX008 Phase 3 Clinical Trial in Dravet Syndrome
“The completion of patient randomization in Study 1 is an important milestone for our ZX008 Phase 3 development program in Dravet syndrome,” said
Study 1 is a three-arm, fixed-dose, placebo-controlled trial with 40 subjects per treatment group being conducted in the U.S.,
In addition to Study 1,
For more information, visit www.zogenix.com.
Forward Looking Statements
Andrew McDonaldFounding Partner, LifeSci Advisors LLC646-597-6987 | Andrew@lifesciadvisors.com